Vanda Pharmaceuticals Inc (VNDA)

Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK

Nov 18, 2024

Nov 17, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Nov 17, 2024

Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024

Nov 13, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria

Nov 13, 2024

Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024

Nov 09, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Nov 09, 2024

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024

Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz

Nov 07, 2024

Nov 07, 2024

Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review

Nov 07, 2024

Nov 07, 2024

Vanda: Q3 Earnings Snapshot - Middletown Press

Nov 07, 2024

Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance

Nov 07, 2024

Nov 06, 2024

Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks

Nov 06, 2024

Nov 06, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 06, 2024

Nov 05, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 05, 2024

Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024

Nov 04, 2024

Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024

Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024

Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024

Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024

Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024

Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024

Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024

Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024

Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024

Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024

Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024

Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024

Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024

Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024

Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024

Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024

Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024

Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024

Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024